Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy
The Food and Drug Administration said Monday it will perform a speedy review of Sarepta Therapeutics' (SRPT) muscular dystrophy gene therapy, and SRPT stock jumped.X Sarepta filed for approval based on three clinical studies of the gene therapy, SRP-9001. But one study, called Embark, is still…#sareptatherapeutics #sarepta #genetherapy #srpt #gene #sareptagene #therapeutics #therapy #fda #embark (Source: Reuters: Health)
Source: Reuters: Health - November 28, 2022 Category: Consumer Health News Source Type: news
Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta ’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy
Regulatory action date of May 29, 2023
SRP-9001 would be the first gene therapy for Duchenne, a one-time treatment designed to treat the underlying cause of DMD by delivering a functional shortened dystrophin to muscle
CAMBRIDGE, Mass., Nov.... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 28, 2022 Category: Drugs & Pharmacology Source Type: news
Megyn Kelly slams Elizabeth Holmes for getting pregnant to ‘try to get less prison time’: ‘Baby won’t have a mom’
Megyn Kelly criticized convicted fraudster Elizabeth Holmes for getting pregnant with her second child as a ploy to come off more sympathetic to the judge in hopes of getting a more lenient prison term. “I hate to agree with the Twitter mob,” Kelly said on her SiriusXM podcast Monday when…#fraudsterelizabeth #elizabethholmes #kelly #megynkelly #kellycriticized #holmes #prisonterm #lenientprison #elizabeth #prison (Source: Reuters: Health)
Source: Reuters: Health - November 22, 2022 Category: Consumer Health News Source Type: news
Gene and Cell Therapies Used in Treatment
Gene therapy offers new hope for people with some forms of inherited retinal dystrophy. Find out what’s available now and how to find a clinical trial. (Source: WebMD Health)
Source: WebMD Health - November 21, 2022 Category: Consumer Health News Source Type: news
Early Diagnosis and Why It Matters
For most types of inherited retinal dystrophy, there is no cure. Find out why early diagnosis is still critical for your quality of life. (Source: WebMD Health)
Source: WebMD Health - November 21, 2022 Category: Consumer Health News Source Type: news
Being Diagnosed With Inherited Retinal Dystrophy
Being diagnosed with a hereditary vision disease is life-changing. Learn how someone with retinitis pigmentosa manages life with low vision. (Source: WebMD Health)
Source: WebMD Health - November 21, 2022 Category: Consumer Health News Source Type: news
What Type of Inherited Retinal Dystrophy Do You Have?
Inherited retinal dystrophy affects your vision. Find out more about the common types. (Source: WebMD Health)
Source: WebMD Health - November 21, 2022 Category: Consumer Health News Source Type: news
Role of 24 H Ambulatory BP Monitoring for Reflex Syncope Role of 24 H Ambulatory BP Monitoring for Reflex Syncope
A new study proposes a novel approach to screen for hypotensive susceptibility in people with a history of reflex syncope, by means of 24 h ambulatory blood pressure monitoring.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 18, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer ’s disease
Phase III GRADUATE studies did not meet their primary endpoints of slowing clinical decline in people with early Alzheimer ’sThe level of beta-amyloid removal by gantenerumab was lower than expectedTopline data will be presented at the Clinical Trials on Alzheimer ’s Disease (CTAD) ConferenceRoche is committed to the Alzheimer ’s community and will continue to develop novel diagnostics and potential treatments for Alzheimer’sBasel, 14 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) du...
Source: Roche Investor Update - November 14, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer ’s disease
Phase III GRADUATE studies did not meet their primary endpoints of slowing clinical decline in people with early Alzheimer ’sThe level of beta-amyloid removal bygantenerumab was lower than expectedTopline data will be presented at the Clinical Trials on Alzheimer ’s Disease (CTAD) ConferenceRoche is committed to the Alzheimer ’s community and will continue to develop novel diagnostics and potential treatments for Alzheimer ’sBasel, 14 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) du...
Source: Roche Investor Update - November 14, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer ’s disease
Phase III GRADUATE studies did not meet their primary endpoints of slowing clinical decline in people with early Alzheimer ’sThe level of beta-amyloid removal bygantenerumab was lower than expectedTopline data will be presented at the Clinical Trials on Alzheimer ’s Disease (CTAD) ConferenceRoche is committed to the Alzheimer ’s community and will continue to develop novel diagnostics and potential treatments for Alzheimer ’sBasel, 14 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) du...
Source: Roche Media News - November 14, 2022 Category: Pharmaceuticals Source Type: news
News at a glance: A new antibiotic, COVID-19 in Antarctica, and a Venus mission deferred
CLIMATE SCIENCE
Space station carbon mapper faces demise
An orbiting fridge-size sensor that uses lasers to map forest structure—key to understanding how much carbon trees sequester—is set to plummet to a fiery destruction in the atmosphere in 2023 unless NASA extends its tenure. Researchers and some U.S. Congress members are lobbying the agency to reconsider its plan to jettison the Global Ecosystem Dynamics Investigation (GEDI) instrument from the International Space Station to make way for a Department of Defense sensor. GEDI measures the height of trees and the quality of habitat they provide...
Source: ScienceNOW - November 10, 2022 Category: Science Source Type: news
Vitamin D deficiency can cause musculoskeletal pain and muscle dystrophy, warns pharmacist
Given the risks, it's vital that you replenish low levels of the sunshine vitamin. (Source: Daily Express - Health)
Source: Daily Express - Health - November 7, 2022 Category: Consumer Health News Source Type: news
What to Know About Diabetes and the Risk of Silent Heart Attacks
At first it seemed like a routine call—something the paramedics had dealt with countless times before. A man in his mid-50s was having a heart attack, and his physician had called for emergency support. But when the paramedics arrived, the physician pulled them aside and told them something peculiar: the man had no cardiovascular symptoms whatsoever.
The man had come to his doctor’s office because he’d woken early the previous morning sweating and with a sharp pain in his left wrist. These symptoms had quickly subsided and he’d gone back to sleep. Later, after going about his day, he’d visited...
Source: TIME: Health - November 4, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate heart health Source Type: news
Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy
Pratteln, Switzerland, and Rockville, MD, USA, October 27, 2022– Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that they have completed the rolling submission of a new drug application (NDA) to the U.S. Food... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - October 27, 2022 Category: Drugs & Pharmacology Source Type: news
